Drug
Dupixent
Dupixent: highest development phase Post-Market, developed by Regeneron. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Regeneron
Trials
| Drug | Phase | Indication |
|---|---|---|
| Dupixent NCT05285839 | Post-Market | Atopic Dermatitis |
Latest
No recent events.
Follow Dupixent on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.